Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pathological Conditions, Signs and Symptoms

ClinicalTrials.gov lists 143,308 trials for Pathological Conditions, Signs and Symptoms or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 749.

MeSH D013568 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 7,903 Phase 1/2 Phase 1/2 3,124 Phase 2 Phase 2 12,125 Phase 2/3 Phase 2/3 1,808 Phase 3 Phase 3 9,657 Phase 4 Phase 4 10,165 Not applicable Not applicable 62,643 Observational Observational 35,669 Phase 1 Phase 1 7,903 Phase 1/2 Phase 1/2 3,124 Phase 2 Phase 2 12,125 Phase 2/3 Phase 2/3 1,808 Phase 3 Phase 3 9,657 Phase 4 Phase 4 10,165 Not applicable Not applicable 62,643 Observational Observational 35,669

Trials per phase (log scale)

2 more sections with rows

24 of the 143,308 trials are tagged with Pathological Conditions, Signs and Symptoms itself; the rest are tagged with a narrower condition beneath it.

Get the Pathological Conditions, Signs and Symptoms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pathological Conditions, Signs and Symptoms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 349 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 9,535

1990: 32 trials (Observational 17, Not applicable 3, Phase 3 3, Phase 2 7, Phase 1/2 1, Phase 1 1) 1991: 48 trials (Observational 25, Not applicable 2, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1 2) 1992: 68 trials (Observational 30, Not applicable 6, Phase 4 1, Phase 3 14, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 6) 1993: 84 trials (Observational 30, Not applicable 9, Phase 4 4, Phase 3 22, Phase 2 12, Phase 1/2 2, Phase 1 5) 1994: 93 trials (Observational 31, Not applicable 16, Phase 4 1, Phase 3 17, Phase 2/3 2, Phase 2 18, Phase 1/2 1, Phase 1 7) 1995: 156 trials (Observational 55, Not applicable 23, Phase 4 3, Phase 3 25, Phase 2/3 2, Phase 2 27, Phase 1/2 8, Phase 1 13) 1996: 168 trials (Observational 51, Not applicable 25, Phase 4 8, Phase 3 35, Phase 2/3 1, Phase 2 32, Phase 1/2 4, Phase 1 12) 1997: 204 trials (Observational 48, Not applicable 37, Phase 4 11, Phase 3 43, Phase 2/3 5, Phase 2 28, Phase 1/2 6, Phase 1 26) 1998: 290 trials (Observational 63, Not applicable 36, Phase 4 12, Phase 3 56, Phase 2/3 6, Phase 2 73, Phase 1/2 12, Phase 1 32) 1999: 420 trials (Observational 102, Not applicable 45, Phase 4 17, Phase 3 70, Phase 2/3 6, Phase 2 109, Phase 1/2 14, Phase 1 57) 2000: 541 trials (Observational 125, Not applicable 87, Phase 4 45, Phase 3 94, Phase 2/3 5, Phase 2 109, Phase 1/2 23, Phase 1 53) 2001: 678 trials (Observational 148, Not applicable 116, Phase 4 57, Phase 3 129, Phase 2/3 14, Phase 2 134, Phase 1/2 27, Phase 1 53) 2002: 880 trials (Observational 122, Not applicable 169, Phase 4 121, Phase 3 208, Phase 2/3 16, Phase 2 155, Phase 1/2 34, Phase 1 55) 2003: 1,259 trials (Other 1, Observational 212, Not applicable 240, Phase 4 193, Phase 3 234, Phase 2/3 38, Phase 2 215, Phase 1/2 57, Phase 1 69) 2004: 1,692 trials (Observational 273, Not applicable 361, Phase 4 243, Phase 3 294, Phase 2/3 40, Phase 2 302, Phase 1/2 58, Phase 1 121) 2005: 2,231 trials (Observational 414, Not applicable 503, Phase 4 268, Phase 3 346, Phase 2/3 51, Phase 2 405, Phase 1/2 84, Phase 1 160) 2006: 2,705 trials (Other 3, Observational 514, Not applicable 614, Phase 4 350, Phase 3 423, Phase 2/3 64, Phase 2 440, Phase 1/2 80, Phase 1 217) 2007: 3,132 trials (Other 1, Observational 624, Not applicable 783, Phase 4 391, Phase 3 419, Phase 2/3 71, Phase 2 504, Phase 1/2 98, Phase 1 241) 2008: 3,497 trials (Other 1, Observational 749, Not applicable 938, Phase 4 428, Phase 3 416, Phase 2/3 88, Phase 2 461, Phase 1/2 112, Phase 1 304) 2009: 3,929 trials (Other 1, Observational 874, Not applicable 1,155, Phase 4 455, Phase 3 419, Phase 2/3 71, Phase 2 535, Phase 1/2 116, Phase 1 303) 2010: 4,168 trials (Observational 1,022, Not applicable 1,324, Phase 4 422, Phase 3 386, Phase 2/3 70, Phase 2 518, Phase 1/2 121, Phase 1 305) 2011: 4,517 trials (Observational 1,085, Not applicable 1,487, Phase 4 467, Phase 3 474, Phase 2/3 76, Phase 2 477, Phase 1/2 125, Phase 1 326) 2012: 4,824 trials (Other 1, Observational 1,110, Not applicable 1,760, Phase 4 468, Phase 3 466, Phase 2/3 59, Phase 2 546, Phase 1/2 118, Phase 1 296) 2013: 4,934 trials (Other 2, Observational 1,118, Not applicable 1,961, Phase 4 463, Phase 3 410, Phase 2/3 60, Phase 2 471, Phase 1/2 145, Phase 1 304) 2014: 5,516 trials (Observational 1,324, Not applicable 2,244, Phase 4 519, Phase 3 372, Phase 2/3 86, Phase 2 489, Phase 1/2 138, Phase 1 344) 2015: 5,774 trials (Other 4, Observational 1,425, Not applicable 2,450, Phase 4 527, Phase 3 398, Phase 2/3 93, Phase 2 459, Phase 1/2 127, Phase 1 291) 2016: 6,297 trials (Other 7, Observational 1,618, Not applicable 2,846, Phase 4 502, Phase 3 357, Phase 2/3 80, Phase 2 449, Phase 1/2 115, Phase 1 323) 2017: 6,580 trials (Other 6, Observational 1,726, Not applicable 3,113, Phase 4 454, Phase 3 334, Phase 2/3 78, Phase 2 454, Phase 1/2 111, Phase 1 304) 2018: 7,217 trials (Other 3, Observational 1,977, Not applicable 3,461, Phase 4 445, Phase 3 343, Phase 2/3 68, Phase 2 476, Phase 1/2 130, Phase 1 314) 2019: 7,668 trials (Other 4, Observational 2,106, Not applicable 3,787, Phase 4 445, Phase 3 322, Phase 2/3 68, Phase 2 471, Phase 1/2 123, Phase 1 342) 2020: 7,338 trials (Other 4, Observational 2,272, Not applicable 3,398, Phase 4 361, Phase 3 299, Phase 2/3 65, Phase 2 447, Phase 1/2 154, Phase 1 338) 2021: 8,921 trials (Other 2, Observational 2,456, Not applicable 4,491, Phase 4 446, Phase 3 373, Phase 2/3 94, Phase 2 521, Phase 1/2 149, Phase 1 389) 2022: 9,012 trials (Other 4, Observational 2,440, Not applicable 4,740, Phase 4 386, Phase 3 331, Phase 2/3 87, Phase 2 464, Phase 1/2 150, Phase 1 410) 2023: 9,403 trials (Other 1, Observational 2,479, Not applicable 5,083, Phase 4 388, Phase 3 320, Phase 2/3 86, Phase 2 470, Phase 1/2 155, Phase 1 421) 2024: 9,432 trials (Other 2, Observational 2,427, Not applicable 5,093, Phase 4 389, Phase 3 315, Phase 2/3 83, Phase 2 514, Phase 1/2 147, Phase 1 462) 2025: 9,535 trials (Other 2, Observational 2,260, Not applicable 5,245, Phase 4 388, Phase 3 352, Phase 2/3 78, Phase 2 572, Phase 1/2 159, Phase 1 479)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 8,826
2025 9,535
2024 9,432
2023 9,403
2022 9,012
2021 8,921
2020 7,338
2019 7,668
2018 7,217
2017 6,580

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 11,000 trials starting in 2026 and about 9,800 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 12,102 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 87,728 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pathological Conditions, Signs and Symptoms trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 7,903
Phase 1/2 3,124
Phase 2 12,125
Phase 2/3 1,808
Phase 3 9,657
Phase 4 10,165
Not applicable 62,643
Observational 35,669
Expanded access 175
Unknown 39

How many Pathological Conditions, Signs and Symptoms trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 7,232
Recruiting 15,600
Enrolling by invitation 1,330
Active, not recruiting 4,821
Available 39

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pathological Conditions, Signs and Symptoms trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 749
Novartis Pharmaceuticals 654
AstraZeneca 641
VA Office of Research and Development 512

Which drugs are being tested for Pathological Conditions, Signs and Symptoms? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 630
+/- Bupivacaine HCl 582
DEXMEDETOMIDINE 506
RITUXIMAB 452
PMI-150 (intranasal ketamine) 364

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 751
Exercise 589
Control (placebo) group 517
SQ Fludarabine 515
A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.) 497

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pathological Conditions, Signs and Symptoms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 27,992 2,516
Emergency Department visit within 90 days of index imaging 26,174 1
Other 19,240 68
Chronic obstructive pulmonary disease 17,905 862
Sepsis 8,995 1,567

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages